Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047181 | 0.91 | NR1H2 (0.37) | MEN1KMT2AHRH3NR1H2NR1H3 | |
| SCHEMBL3047269 | 0.90 | MEN1 (0.37) | MEN1KMT2ANR1H2NR1H3LMNA | |
| SCHEMBL3038196 | 0.90 | NR1H2 (0.38) | MEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL3046959 | 0.89 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL3039560 | 0.89 | NR1H2 (0.40) | NR1H2NR1H3 | |
| SCHEMBL3050277 | 0.88 | HRH3 (0.37) | HRH3NR1H2NR1H3 | |
| SCHEMBL3048132 | 0.88 | NR1H2 (0.35) | NR1H2NR1H3 | |
| SCHEMBL3047413 | 0.87 | NR1H2 (0.36) | HRH3NR1H2NR1H3SMN1; SMN2 | |
| SCHEMBL3045879 | 0.87 | HRH3 (0.38) | HRH3NR1H2NR1H3MCHR1 | |
| SCHEMBL3039603 | 0.87 | NR1H2 (0.33) | MEN1KMT2ANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | MEN1 1165/4885KMT2A 320/4885HRH3 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.